Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14885531 | 0.87 | ALDH1A1 (0.31) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL537196 | 0.75 | — | — | |
| SCHEMBL13244491 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TSHRHSD17B10SLC7A5 | |
| SCHEMBL2370082 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TSHRHSD17B10SLC7A5 | |
| SCHEMBL18674361 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TSHRHSD17B10SLC7A5 | |
| Hydrochloric Acid SCHEMBL28864197 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL27565551 | 0.70 | — | — | |
| SCHEMBL2633201 | 0.68 | — | — | |
| SCHEMBL11664834 | 0.68 | — | — | |
| SCHEMBL597106 | 0.68 | ALDH1A1 (0.50) | ALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109915-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240083906-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARM INC (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2024026359-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH PARASITIC WORMS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4007753-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-4007638-A1 | PYRIDINE DERIVATIVES AS KIF18A INHIBITORS | Amgen Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022038617-A1 | HOT MELT ADHESIVE ARTICLES | MATZA SAGI (IL) | 2022-02-24 | — | — | WO | disclosed |
| WO-2021255681-A1 | A SIMPLE PROCESS FOR THE PREPARATION OF FAVIPIRAVIR AND ITS INTERMEDIATES THEREOF | HIKAL LIMITED (IN) | 2021-12-23 | — | — | WO | disclosed |
| US-11014928-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2021026099-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021026100-A1 | PYRIDINE DERIVATIVES AS KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20050256102-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005082430-A1 | BIOMATERIALS FOR ENHANCED HEALING | BOSTON SCIENTIFIC LIMITED (INCORPORATED IN IRELAND) (BB) | 2005-09-09 | — | — | WO | disclosed |
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC (BM) | 2005-08-04 | — | — | US | disclosed |
| US-6881743-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| WO-2005033086-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-14 | — | — | WO | disclosed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | disclosed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-5602141-A | WATER SOLUBILITY; TREATMENT OF LEUKEMIA | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | ERBB2, ERBB3, ERBB4 | ALDH1A1 3930/4885TSHR 926/4885HSD17B10 4597/4885 |
| US-20050256102-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | ALDH1A1 3815/4885TSHR 4809/4885HSD17B10 2449/4885 |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | ALDH1A1 544/4885TSHR 3059/4885HSD17B10 516/4885 |
| US-20240109915-A1 | NOVEL ACC INHIBITORS | CBR3, NAT1, ACACB | ALDH1A1 2330/4885TSHR 108/4885HSD17B10 102/4885 |
| US-11014928-B2 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | ALDH1A1 3815/4885TSHR 4809/4885HSD17B10 2449/4885 |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | ALDH1A1 571/4885TSHR 3181/4885HSD17B10 516/4885 |
| US-20240083906-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | ALDH1A1 3815/4885TSHR 4809/4885HSD17B10 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.